Cellyan Biotechnology Co. Ltd. HKPD
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in Cellyan Biotechnology Co., Ltd's annual report to the U.S. Securities and Exchange Commission, filed 7 August 2026. Every sentence was checked against that document before publication.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 1 cents this year.
The 3-year record
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | 0.0 | 0.0 |
| Free cash flow $B | 0.0 | −0.0 | 0.0 |
| EPS, diluted $ | −0.00 | 0.18 | 0.15 |
| Dividend / sh $ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — |
| ROE % | −0.6 | 55.0 | 170.6 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
This company against its peers
Company facts, as filed
Reconciled in 3 of the 3 fiscal years we could check. 32 checks were skipped: the balance sheet is not tagged before 2023. 15 checks were skipped: EPS is not tagged before 2022. 15 checks were skipped: revenue is not tagged before 2022.